LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of post-induction lenalidomide in
patients with de novo AML with deletion 5q cytogenetic abnormality (del (5q)) or monosomy 5
(-5), who obtained complete remission after conventional induction chemotherapy. So, too, for
those who no obtained response treatment (total resistance) or partial remission.
At the same time, the study evaluate the security of lenalidomide.